Cargando…

Challenges in the clinical development of PI3K inhibitors

The PI3K/Akt/mTOR pathway is one of the most frequently dysregulated signaling pathways in cancer and an important target for drug development. PI3K signaling plays a fundamental role in tumorigenesis, governing cell proliferation, survival, motility, and angiogenesis. Activation of the pathway is f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Massacesi, Cristian, Tomaso, Emmanuelle, Fretault, Nathalie, Hirawat, Samit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2013
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666091/ https://www.ncbi.nlm.nih.gov/pubmed/23551097 http://dx.doi.org/10.1111/nyas.12060

Ejemplares similares

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
por: Massacesi, Cristian, et al.
Publicado: (2016)

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
por: O’Brien, Neil A., et al.
Publicado: (2020)

Development and safety of PI3K inhibitors in cancer
por: Yu, Miaomiao, et al.
Publicado: (2023)

Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy
por: Sirico, Marianna, et al.
Publicado: (2023)

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
por: Mishra, Rosalin, et al.
Publicado: (2021)

Multiorgan Metastasis of Human HER-2(+) Breast Cancer in Rag2(−/−);Il2rg(−/−) Mice and Treatment with PI3K Inhibitor
por: Nanni, Patrizia, et al.
Publicado: (2012)

Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
por: Zhao, Hua-fu, et al.
Publicado: (2017)

PI3K inhibitors in inflammation, autoimmunity and cancer
por: Stark, Anne-Katrien, et al.
Publicado: (2015)

Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
por: Rewcastle, Gordon W, et al.
Publicado: (2017)

PI3Kα Inhibitors That Inhibit Metastasis
por: Schmidt-Kittler, Oleg, et al.
Publicado: (2010)

Phytochemicals and PI3K Inhibitors in Cancer—An Insight
por: Suvarna, Vasanti, et al.
Publicado: (2017)

PI3K inhibitors: review and new strategies
por: Zhang, Mingzhen, et al.
Publicado: (2020)

PI3K inhibitors in thrombosis and cardiovascular disease
por: Durrant, Tom N., et al.
Publicado: (2020)

PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives
por: Fuso, Paola, et al.
Publicado: (2022)

Roles of PI3K pan-inhibitors and PI3K-δ inhibitors in allergic lung inflammation: a systematic review and meta-analysis
por: Kim, Jong Seung, et al.
Publicado: (2020)

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
por: Till, Kathleen J., et al.
Publicado: (2023)

The present and future of PI3K inhibitors for cancer therapy
por: Castel, Pau, et al.
Publicado: (2021)

Development of New Thiophene-Containing Triaryl Pyrazoline Derivatives as PI3Kγ Inhibitors
por: Yang, Bing, et al.
Publicado: (2022)

Developing a novel dual PI3K–mTOR inhibitor from the prodrug of a metabolite
por: Zhou, Yan, et al.
Publicado: (2017)

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Structural Determinants of Isoform Selectivity in PI3K Inhibitors
por: Miller, Michelle S., et al.
Publicado: (2019)

Efficacy of PI3K inhibitors in advanced breast cancer
por: Verret, B, et al.
Publicado: (2019)

PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise
por: Bou Zeid, Naji, et al.
Publicado: (2023)

Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR
por: Heffron, Timothy P., et al.
Publicado: (2016)

Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor
por: Juric, Dejan, et al.
Publicado: (2014)

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
por: Brandão, M, et al.
Publicado: (2019)

The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases
por: Banham-Hall, Edward, et al.
Publicado: (2012)

Buparlisib is a brain penetrable pan-PI3K inhibitor
por: de Gooijer, Mark C., et al.
Publicado: (2018)

Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
por: Hopkins, Benjamin D., et al.
Publicado: (2018)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer
por: Hashemzadeh, Kamelia, et al.
Publicado: (2019)

PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors
por: Payne, S N, et al.
Publicado: (2015)

ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors
por: Rehman, Hasibur, et al.
Publicado: (2022)

Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
por: Shuttleworth, S.J, et al.
Publicado: (2011)

Combination effects of sorafenib with PI3K inhibitors under hypoxia in colorectal cancer
por: Bhatia, Dimple R, et al.
Publicado: (2016)

Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer
por: Rodriguez-Freixinos, Victor, et al.
Publicado: (2019)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
por: Yahiaoui, Anella, et al.
Publicado: (2017)

Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor
por: Cai, Yu, et al.
Publicado: (2020)

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome
por: Rao, V. Koneti, et al.
Publicado: (2023)

Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer
por: Weigelt, Britta, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_i291au0htaknb9ed1r3durnq88